Yamazaki T, Imoto T, Hayashi N, Watanabe S, Kozaki H, Abe T
Arch Otorhinolaryngol. 1982;234(1):97-104. doi: 10.1007/BF00453541.
According to a nationwide survey in 1977 and average of 54.7% of Menière's disease patients were unable to function normally in their daily lives. These patients mostly complained of repeated attacks of vertigo (male 40.3%, female 29.2%) (Watanabe et al. 1980). For the purpose of improving the repeated attacks of vertigo, Isosorbide as an oral hyperosmotic diuretic was first administered orally to 21 patients with Menière's disease from November 1979 to January 1981 for reducing the endolymphatic hydrops that can be presumed to be of pathogenetic importance. The electrocochleographic examinations were carried out on these patients at the same time. Usually, the SP/AP wave form in the electrocochleographic examinations appears to be more abnormal in patients with a fluctuating hearing loss or a flat hearing loss. The average of negative SP/AP in 24 patients with Meniére's disease was 0.54. The indication of Isosorbide administration was determined by this particular SP/AP wave abnormality, and clinical of Isosorbide for the patients with Menière's disease were evaluated. In 18 patients who experienced relief, attack of vertigo did not occur in 12 (63%) and vertigo was relieved in six (31%). In two patients with long administration, hearing improvement could already be observed during the period of treatment. The electrocochleographic examinations showed a decrease in the SP/AP wave form. In two patients with short administration, hearing loss was temporarily observed in middle and low frequencies; the hearing loss later improved more than before treatment in these patients. In only one patient, aggravation of hearing was observed after administration, but whether it was a side effect or not, remains to be understood. The period of observation of these results was a mean value of 4 months and 12 days. The Isosorbide therapy in patients with Menière's disease in expected to replace saccus surgery.
根据1977年的一项全国性调查，梅尼埃病患者平均有54.7%无法正常进行日常生活。这些患者大多抱怨眩晕反复发作（男性40.3%，女性29.2%）（渡边等人，1980年）。为了改善眩晕的反复发作，1979年11月至1981年1月，首先对21例梅尼埃病患者口服异山梨醇这种口服高渗利尿剂，以减少可推测具有致病重要性的内淋巴积水。同时对这些患者进行了耳蜗电图检查。通常，在耳蜗电图检查中，听力波动下降或听力平坦下降的患者，其SP/AP波形似乎更异常。24例梅尼埃病患者的负SP/AP平均值为0.54。根据这种特定的SP/AP波形异常来确定异山梨醇的给药指征，并对梅尼埃病患者使用异山梨醇的临床效果进行评估。在18例症状缓解的患者中，12例（63%）未再发生眩晕发作，6例（31%）眩晕得到缓解。在2例长期服药的患者中，在治疗期间已经观察到听力改善。耳蜗电图检查显示SP/AP波形下降。在2例短期服药的患者中，中低频出现了暂时性听力损失；这些患者的听力损失后来比治疗前有了更大改善。只有1例患者在服药后出现听力加重，但这是否为副作用仍有待明确。这些结果的观察期平均为4个月零12天。梅尼埃病患者的异山梨醇疗法有望取代内淋巴囊手术。
